Equities research analysts at Jefferies Group began coverage on shares of BioScrip Inc. (NASDAQ:BIOS) in a note issued to investors on Tuesday. The brokerage set a “buy” rating and a $2.50 price target on the stock. Jefferies Group’s price target indicates a potential upside of 82.48% from the stock’s current price.
Separately, Zacks Investment Research lowered BioScrip from a “buy” rating to a “hold” rating in a research report on Friday, August 12th.
Shares of BioScrip (NASDAQ:BIOS) traded up 3.79% during midday trading on Tuesday, hitting $1.37. The stock had a trading volume of 556,346 shares. The stock has a 50 day moving average price of $2.33 and a 200-day moving average price of $2.60. BioScrip has a 52 week low of $1.15 and a 52 week high of $3.43. The stock’s market capitalization is $161.22 million.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.07. The company earned $224.50 million during the quarter, compared to analyst estimates of $223.26 million. BioScrip’s revenue was down 9.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.38) EPS. Equities research analysts anticipate that BioScrip will post ($0.39) earnings per share for the current year.
In other news, Director R Carter Pate acquired 20,000 shares of the firm’s stock in a transaction on Thursday, November 10th. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $26,000.00. Following the transaction, the director now owns 84,000 shares of the company’s stock, valued at $109,200. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 2.30% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Gabelli Funds LLC raised its position in shares of BioScrip by 23.8% in the second quarter. Gabelli Funds LLC now owns 14,483,253 shares of the company’s stock worth $36,932,000 after buying an additional 2,785,536 shares during the last quarter. Coliseum Capital Management LLC raised its position in shares of BioScrip by 295.3% in the second quarter. Coliseum Capital Management LLC now owns 5,622,410 shares of the company’s stock worth $14,337,000 after buying an additional 4,200,000 shares during the last quarter. Ardsley Advisory Partners purchased a new position in shares of BioScrip during the third quarter worth approximately $12,521,000. Vanguard Group Inc. raised its position in shares of BioScrip by 36.5% in the second quarter. Vanguard Group Inc. now owns 3,446,346 shares of the company’s stock worth $8,788,000 after buying an additional 922,094 shares during the last quarter. Finally, BlackRock Fund Advisors raised its position in shares of BioScrip by 73.5% in the third quarter. BlackRock Fund Advisors now owns 3,043,453 shares of the company’s stock worth $8,796,000 after buying an additional 1,289,065 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.